Conformis Announces Positive Results from Customized iTotal PS Total Knee Replacement Comparative Study

First study of iTotal PS customized implants demonstrated more normal kinematics compared with leading off-the-shelf implants

Bedford, Mass. – April 12, 2017 (GLOBE NEWSWIRE)  Conformis, Inc. (NASDAQ:CFMS), a medical technology company that offers joint replacement implants customized to fit each patient’s unique anatomy, today announced results from the first study of its iTotal® PS total knee replacement presented at the 2017 British Association for Surgery of the Knee (BASK) Annual Meeting.

Researchers at a leading academic institution compared the knee motion, or kinematics, of patients implanted with a Conformis iTotal PS customized total knee replacement to patients implanted with an off-the-shelf Zimmer-Biomet NexGen® PS total knee replacement. Similar to previously reported studies with the iTotal CR, this study demonstrated that Conformis iTotal PS patients’ knee motion patterns more closely resemble those of a normal knee than patients’ knee motion patterns with the traditional, off-the-shelf implant.

When a healthy knee bends, the lateral condyle, or outer portion of the end of the thigh bone or femur, rolls back on the shin bone or tibia and rotates externally, towards the outside of the knee. In this single-center study, financially supported by Conformis, researchers assessed the kinematics of 31 patients (13 patients with a Conformis iTotal PS implant and 18 patients with an off-the-shelf implant) at least six months after surgery using advanced real-time mobile x-ray imaging and 2D-3D registration. Patients who received a Conformis iTotal PS demonstrated greater average range of motion during a deep knee bend (112° vs. 94°*). Additionally, iTotal PS patients saw greater lateral femoral rollback (11.73mm vs. 4.69mm*), medial translation (2.8mm vs. 1.0mm*) and greater axial rotation (10.85° vs. 7.58°) during deep knee bend, which is consistent with normal knee motion. (Note: * indicates statistical significance with p≤0.05)

“All findings from this study suggest that the iTotal PS has the kinematic and functional benefits that have been demonstrated with iTotal CR compared with traditional, off-the-shelf implants,” said William Kurtz, MD, Chief of Orthopedics at St Thomas Hospital in Nashville, TN and clinical investigator in the study. “Patients want to return to everyday activities after their recovery and, in my experience, maintaining normal knee motion is critical to achieving those goals. I have found that when you alter patients’ normal kinematics, as happens with off-the-shelf implants, there’s a greater risk that the patient won’t be able to return to their regular activities.”

In addition, two studies, financially supported by Conformis, were presented at BASK highlighting the variability in femoral and tibial anatomy which cannot be replicated by off-the-shelf implants, which are offered in a limited number of shapes and sizes:

  • A retrospective review of 24,042 CT data sets used to design customized iTotal implants found that 61% of knees exhibited a distal femoral offset of >1mm. Additionally, 83% exhibited >2mm of posterior condylar offset. Off-the-shelf implants are designed with fixed condylar offsets, which are unable to retain the natural condylar shape of the knee.
  • A similar analysis was conducted on tibial implants and found that the tibial trays were within 2mm or less of symmetrical only 12% of the time, while 22% were found to have asymmetry >5mm. The authors concluded that tibial trays that are either symmetric or have a fixed asymmetry based on medio-lateral size, as off-the-shelf implants do, may face challenges between maintaining proper rotation and adequate coverage.

“In its first year of release iTotal PS has met our expectations in terms of surgeon adoption and patient outcomes,” said Mark Augusti, MBA, Chief Executive Officer and President of Conformis. “Clinical research has demonstrated our implants offer superior clinical outcomes compared with off-the-shelf implants. We are committed to continuing investing in the clinical study of our implants to demonstrate their superior clinical and economic value for patients, surgeons, hospitals, and payers across the healthcare continuum.”

About Conformis, Inc.
Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient’s unique anatomy. Conformis offers a broad line of customized knee implants and pre-sterilized, single-use instruments delivered in a single package to the hospital. In clinical studies, Conformis iTotal CR demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses approximately 450 issued patents and pending patent applications that cover customized implants and patient-specific instrumentation for all major joints.

For more information, visit To receive future releases in e-mail alerts, sign up at

Cautionary Statement Regarding Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Conformis, including statements about Conformis’ clinical strategy, the potential clinical, economic or other impacts and advantages of using customized implants and the commercial launch of iTotal PS, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to our clinical studies and the other risks and uncertainties described in the “Risk Factors” sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Conformis’s views as of the date hereof. Conformis anticipates that subsequent events and developments may cause Conformis’s views to change. However, while Conformis may elect to update these forward-looking statements at some point in the future, Conformis specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Conformis’s views as of any date subsequent to the date hereof.

Investor Contact:
Oksana Bradley
(781) 374-5598

Media Contacts:
Bill Berry
Berry & Company Public Relations
(212) 253-8881

Lynn Granito
Berry & Company Public Relations
(212) 253-8881


Patient Helpline 855-564-7682

Find A Doctor Patient Helpline